• Vaccine Name: Diphtheria & Tetanus Toxoids Adsorbed
• Target Pathogen: Clostridium tetani
• Target Disease: Tetanus
• Product Name: Diphtheria and Tetanus Toxoids Adsorbed
• Tradename: No Tradename
• Manufacturer: Sanofi Pasteur Inc
• Vaccine Ontology ID: VO_0000033
• CDC CVX code: 28
• Type: Toxoid vaccine
• Status: Licensed
• Location Licensed: USA (FDA License #1725), Canada
• Host Species for Licensed Use: Human
• Antigen: Detoxified toxins from Corynebacterium diphtheriae and Clostridium tetani (FDA: dttadLB)
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001240
  • Description: This vaccine is for intramuscular use. It is a sterile suspension of alum-precipitated (aluminum potassium sulfate) toxoid in an isotonic sodium chloride solution (FDA: dttadLB).
• Preparation: Clostridium tetani cultures are grown in a peptone-based medium containing bovine extract. Both toxins are detoxified with formaldehyde. The detoxified materials are then separately purified by serial ammonium sulfate fractionation and diafiltration.
• Immunization Route: Intramuscular injection (i.m.)
• Storage: Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.
• Approved Age for Licensed Use: Diphtheria and Tetanus Toxoids Adsorbed (For Pediatric Use) (DT) is indicated for active immunization of children up to age 7 years against diphtheria and tetanus. Immunization should be started at 6 weeks to 2 months of age and be completed before the seventh birthday. Immunization always should be started at once if diphtheria is present in the community. This vaccine should NOT be used for immunizing persons 7 years of age and older. For persons 7 years of age and older, the recommended vaccine is Tetanus and Diphtheria Toxoids Adsorbed for Adult Use (Td) (FDA: Tetanus Toxoid Adsorbed by Sanofi Pasteur Inc).
• Contraindication: Hypersensitivity to any component of the vaccine is a contraindication, use of related vaccine after an immediate anaphylactic reaction associated with a previous dose, and history of systemic allergic or neurologic reactions following a previous dose (FDA: dttadLB).
• Description: This vaccine is for intramuscular use. It is a sterile suspension of alum-precipitated (aluminum potassium sulfate) toxoid in an isotonic sodium chloride solution (FDA: dttadLB).

Human Response

• Immune Response: In one clinical trial, protective levels of diphtheria and tetanus antitoxins were detected in 100% of the children following two doses of the vaccine (FDA: dttadLB).
• Side Effects: Adverse reactions may be local and include redness, warmth, edema, induration, with or without tenderness, as well as urticaria, and rash. Malaise, transient fever, pain, hypotension, nausea and arthralgia may develop as well (FDA: dttadLB).
• Efficacy: A complete vaccination series substantially reduces the risk of developing diphtheria, and vaccinated persons who develop disease have milder illness. Protection lasts at least 10 years. Vaccination does not, however, eliminate carriage of C. diphtheriae in the pharynx or nose or on the skin (FDA: dttadLB).